Ensysce Biosciences' PF614-MPAR Enters Final Stage of Phase 1 Study
Ensysce Biosciences' PF614-MPAR, could be the industry's first overdose protection pain product, now entering a final Phase 1 study with Quotient Sciences.
HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801
HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company focusing on novel multifunctional therapeutics for metabolic and digestive diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have signed an agreement to support HighTide’s HTD1801 program.
Quotient Sciences Celebrates Grand Opening of New Alnwick Drug Substance Facility With Official Ribbon Cutting
Quotient Sciences Celebrates Grand Opening of New Drug Substance Facility with Official Ribbon Cutting at our Alnwick facility.
Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03
Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03.
Oxilio announces start of its first clinical trial with OXL001
Oxilio has commenced first human subject dosing of OXL001. The product leverages the Quotient Sciences Translational Pharmaceutics® platform for drug development.
Emplicure AB Announce Completion of Phase I PK study for EMPLI03 with Quotient Sciences
Emplicure AB reported dosing in the first Phase I pharmacokinetic study for EMPLI03, intended for the treatment of moderate to severe pain. The program is supported by Quotient Sciences Translational Pharmaceutics® platform.